provider portal
Wesper Journal
Many people experience immediate mental clarity and reduced brain fog after just one night of using CPAP therapy, as it alleviates airway obstruction and enhances sleep quality. The therapy delivers consistent airway support, leading to improved oxygen levels and restorative...
Continue reading
Impilo and Wesper are revolutionizing sleep apnea diagnosis and management by combining Remote Patient Monitoring (RPM) with advanced at-home sleep testing. Traditional sleep studies are cumbersome, but Impilo’s seamless device integration enables real-time health tracking, while Wesper’s wireless biometric patches provide high-resolution sleep data without intrusive equipment. This powerful integration allows for early detection, personalized treatment adjustments, and increased patient engagement , ensuring more accurate diagnoses and better long-term outcomes. By leveraging cutting-edge technology, Impilo and Wesper are making sleep apnea care more accessible, precise, and proactive —empowering patients to take control of their sleep health.
Continue reading
This article explores the relationship between BMI, age, and gender in obstructive sleep apnea (OSA) severity and hypoxic burden. Analyzing two patient cohorts, the study finds that higher BMI is linked to increased apnea-hypopnea index (AHI) and hypoxic burden, though its effect plateaus in severe obesity. Age and male gender emerge as stronger predictors of OSA severity in obese individuals. The findings highlight the potential of GLP-1-induced weight loss to reduce OSA severity but emphasize the need for a multimodal approach, integrating weight management with traditional OSA treatments like CPAP for optimal patient outcomes.
Continue reading
Discover how Zepbound® (tirzepatide), the first FDA-approved medication for obstructive sleep apnea (OSA) in adults with obesity, is revolutionizing treatment. Combining effective weight management with symptom relief, Zepbound offers a groundbreaking solution that enhances sleep quality, simplifies care pathways, and improves overall health outcomes. Learn more about this transformative advancement in OSA therapy.
Continue reading
Discover how Zepbound® (tirzepatide), the first FDA-approved medication for obstructive sleep apnea (OSA) in adults with obesity, is revolutionizing treatment. Combining effective weight management with symptom relief, Zepbound offers a groundbreaking solution that enhances sleep quality, simplifies care pathways, and improves overall health outcomes. Learn more about this transformative advancement in OSA therapy.
Continue reading
